ERBB2 and breast cancer: Several other targeted therapies for BC brain metastasis are under clinical evaluation; for example, GDC-0084, a PI3K/Akt/mTOR pathway inhibitor, is being used in combination with trastuzumab for HER2-positive BC brain metastasis (ClinicalTrials.gov identifier: NCT03765983) [89].